| 章必成,彭 敏,宋启斌.肠道微生物群与免疫治疗疗效的关系[J].肿瘤学杂志,2018,24(11):1056-1059. |
| 肠道微生物群与免疫治疗疗效的关系 |
| Relationship Between Gut Microbiome and Efficacy of Immunotherapy |
| 投稿时间：2018-03-23 |
| DOI：10.11735/j.issn.1671-170X.2018.11.B004 |
|
 |
| 中文关键词: 肠道微生物群 免疫治疗 生物标志物 |
| 英文关键词:gut microbiome immunotherapy biomarker |
| 基金项目: |
|
| 摘要点击次数: 2252 |
| 全文下载次数: 634 |
| 中文摘要: |
| 摘 要：肠道微生物群是一个极其复杂的群体，因其重要的作用被认为是人体器官或人类的“第二基因组”。肠道微生物群不仅与肠道免疫的关系密切，而且影响了全身免疫系统。近年的研究显示，肠道微生物群可以影响免疫治疗疗效。由于可能导致肠道微生物群失调，因此在接受免疫检查点抑制剂（ICIs）治疗前后应尽量避免使用抗生素；此外，对部分患者进行粪便移植有望提高免疫治疗疗效。基于上述原因，管理肠道微生物群也成为了免疫治疗管理的一个重要内容，肠道微生物群有望成为一个潜在的预测免疫治疗疗效的生物标志物。 |
| 英文摘要: |
| Abstract：Gut microbiome is a complicated group，which may be considered as a body organ or the second genome for its important role. Gut microbiome not only contributes to gut immunity，but also affects general immune system. Recent researches have shown that gut microbiome may affect the efficacy of immunotherapy. To avoid disturb the gut microbiota，antibiotics should be avoided as far as possible before and after immune checkpoint inhibitors (ICIs) therapy. Furthermore，fecal microbiota transplantation may improve the immunotherapeutic effects in some specific patients. Based on the above facts，the administration of gut microbiome may become an important content of immunotherapy，and might be used as a potential biomarker for the predicting efficacy of immunotherapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|